查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1462625

到 2030 年免疫組織化學 (IHC) 市場預測：按產品、應用、最終用戶和地區分類的全球分析

Immunohistochemistry (IHC) Market Forecasts to 2030 - Global Analysis By Product (Antibodies, Reagents and Other Products), Application (Diagnostic Application, Research application and Other Applications), End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球免疫組織化學 (IHC) 市場規模為 25 億美元，預計到 2030 年將達到 47.2 億美元，預測期內年複合成長率為 9.50%。

免疫組織化學 (IHC) 是一種用於病理學和生物醫學研究的強大技術，可可視覺化組織樣本中特定蛋白質和抗原的存在、定位和豐度。它使用與固定組織切片中的目標蛋白結合的抗體。透過抗原修復、封閉、一抗孵育和二抗檢測等一系列步驟，IHC 能夠辨識特定的細胞成分和標記。

根據美國癌症協會2023年癌症統計數據，預計2023年美國將診斷出196萬新發癌症病例，高於2021年的189萬例。

更多地採用伴同性診斷

伴同性診斷透過幫助為每位患者選擇最有效的治療方法，在個人化醫療中發揮重要作用。免疫組織化學技術對於伴同性診斷至關重要，可以識別組織內的特定生物標記和分子標靶。隨著精準醫學的不斷發展，對免疫組織化學技術支援的伴同性診斷的需求不斷增加，特別是在腫瘤學和其他需要標靶治療的領域。隨著醫療保健提供者根據患者特定特徵和分子譜優先考慮客製化治療方法，預計這一趨勢將推動免疫組織化學市場的擴張。

有限的標準化

有限的標準化是指缺乏普遍接受的樣品製備、染色技術和結果解釋的方案或指南。這種標準化的缺乏給研究人員和臨床醫生在不同的實驗室和平台上獲得一致和可重複的結果帶來了挑戰。這會導致染色強度、特異性和靈敏度的變化，影響 IHC資料的可靠性和可比性。因此，這項限制阻礙了 IHC 在臨床診斷和研究應用中的普及，限制了其導致治療決策和科學理解進步的潛力。

癌症研究與診斷

IHC 可以準確檢測和定位組織樣本中的特定蛋白質，從而幫助癌症診斷、預後和治療計劃。 IHC 技術的進步使研究人員和臨床醫生能夠識別與各種癌症類型相關的生物標記，從而實現個人化醫療方法。該技術還促進了腫瘤微環境的研究，有助於更深入地了解癌症生物學和潛在的治療標靶。隨著對準確癌症診斷和標靶治療的需求持續成長，IHC 市場有望進一步擴大並提供創新的解決方案，以改善患者的治療和結果。

價格敏感度

價格敏感度威脅是指顧客對價格變動高度敏感所帶來的風險。 IHC 涉及昂貴的試劑、設備和專業知識，因此定價在購買決策中起著重要作用。在價格敏感的市場中，如果價格上漲，客戶可能會選擇更便宜的替代品或減少使用。因此，對 IHC 產品和服務的需求可能會減少，從而影響該領域公司的收益和報酬率。為了減輕這種威脅，公司必須仔細平衡定價策略與維持產品品質和價值提案，同時也要考慮競爭格局和顧客需求。

COVID-19 的影響：

人們越來越關注了解病毒並開發有效的診斷和治療方法，導致對檢測病毒抗原和評估病毒組織損傷的 IHC 測試的需求激增。此外，關閉期間醫療服務和研究活動的中斷暫時減緩了市場成長。然而，疫情也加速了 IHC 檢測和自動化技術的進步，從而提高了測試過程的效率和準確性。總體而言，雖然疫情帶來了挑戰，但它凸顯了 IHC 在疾病診斷和管理中的重要性，這可能會推動市場的長期成長。

預計設備產業在預測期內將是最大的。

由於技術進步導致更有效率和方便用戶使用的設備的開發，設備領域經歷了顯著的成長。癌症和慢性病的盛行率不斷上升，刺激了對 IHC 等診斷技術的需求，從而推動了相關設備市場的發展。此外，全球醫療保健支出的增加促使醫療機構投資現代設備，以提供更好的患者照護。此外，免疫組織化學技術在研究和藥物開發中的日益成長的應用進一步推動了該領域設備的需求。

研究應用預計在預測期內具有最高的年複合成長率

隨著更先進、更靈敏的 IHC 檢測方法的產生，以滿足複雜的研究需求，研究應用領域正在經歷顯著的成長。腫瘤學、神經科學和免疫學等領域研究範圍的擴大正在推動對 IHC 技術的需求，以分析組織樣本以進行生物標記識別和表徵。此外，學術機構、研究機構和生物技術公司之間的合作正在推動 IHC 在各種研究計劃中的採用。此外，全球生物醫學研究支出的增加使得利用 IHC 探索新的應用和檢驗潛在的治療標靶成為可能，進一步推動了這一領域的成長。

比最大的地區

由於癌症等慢性疾病的盛行率不斷上升、對個人化醫療的需求不斷成長以及診斷技術的進步，北美地區的免疫組織化學 (IHC) 領域呈現顯著成長。有利的報銷政策、強大的醫療基礎設施以及主要市場參與者的強大影響力正在促進北美 IHC 市場的擴張。此外，由於不斷努力提高診斷技術的效率和準確性，對研發活動的投資不斷增加，這進一步推動了市場的成長。

年複合成長率最高的地區：

由於人口老化的增加，亞太地區正在經歷顯著的成長。中國和印度等國家不斷成長的醫療保健支出和基礎設施發展正在促進市場擴張。此外，自動化和數位病理學等技術進步正在提高免疫組織化學測試的效率和準確性，進一步推動市場成長。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次研究資料
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19 的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球免疫組織化學 (IHC) 市場：依產品

  • 抗體
    • 一抗
    • 二抗
  • 試劑
    • 沖淡
    • 蛋白水解酶
    • 封閉血清和試劑
    • 固定試劑
    • 組織學染色
    • 呈色受質
    • 有機溶劑
    • 穩定劑
    • 安裝方案
    • 抗原修復液
    • 其他試劑
  • 套件
    • 動物組織 IHC套件
    • 人體組織 IHC套件
  • 裝置
    • 幻燈片掃描儀
    • 自動蓋拖鞋
    • 切片機
    • 視覺化裝置
    • 滑動貼標機
    • 組織微陣列
    • 石蠟分配器
    • 玻片染色系統
    • 組織處理系統
    • 其他設備
  • 其他產品

第6章全球免疫組織化學 (IHC) 市場：依應用分類

  • 診斷用途
    • 癌症
    • 感染疾病
    • 自體免疫疾病
    • 腎臟疾病
    • 神經系統疾病
    • 眼科
    • 牙科疾病
    • 心血管
    • 皮膚科
    • 其他診斷應用
  • 研究用途
    • 藥物開發和測試
    • 發育生物學
    • 幹細胞研究
    • 法醫學應用
    • 其他研究用途
  • 其他用途

第7章全球免疫組織化學 (IHC) 市場：按最終用戶分類

  • 法醫學研究所
  • 生物製藥公司
  • 醫院和診斷實驗室
  • 學術研究所
  • 其他最終用戶

第8章全球免疫組織化學 (IHC) 市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第9章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第 10 章 公司概況

  • Abcam PLC
  • Agilent Technologies, Inc.
  • Becton Dickinson and Company
  • Bio SB
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • Cell Signaling Technology, Inc.
  • Danaher Corporation
  • F. Hoffmann-LA Roche AG
  • Merck KGaA
  • PerkinElmer, Inc.
  • Takara Bio
  • Thermo Fisher Scientific Inc.
Product Code: SMRC25676

According to Stratistics MRC, the Global Immunohistochemistry (IHC) Market is accounted for $2.50 billion in 2023 and is expected to reach $4.72 billion by 2030 growing at a CAGR of 9.50% during the forecast period. Immunohistochemistry (IHC) is a powerful technique used in the field of pathology and biomedical research to visualize the presence, localization, and abundance of specific proteins or antigens within tissue samples. It involves the use of antibodies that bind to target proteins in fixed tissue sections. Through a series of steps, including antigen retrieval, blocking, primary antibody incubation, and detection with a secondary antibody, IHC enables the identification of specific cellular components or markers.

According to the American Cancer Society 2023 Cancer Statistics, it is estimated that about 1.96 million new cases of cancer would be diagnosed in the United States in 2023, as compared to 1.89 million in 2021.

Market Dynamics:

Driver:

Increasing adoption of companion diagnostics

Companion diagnostics play a crucial role in personalized medicine by aiding in the selection of the most effective treatment for individual patients. Immunohistochemistry techniques are integral to companion diagnostics, enabling the identification of specific biomarkers and molecular targets within tissues. As precision medicine continues to gain traction, demand for companion diagnostics supported by immunohistochemistry techniques is growing, particularly in oncology and other areas requiring targeted therapies. This trend is expected to drive the expansion of the immunohistochemistry market as healthcare providers prioritize tailored treatment approaches based on patients' unique characteristics and molecular profiles.

Restraint:

Limited standardization

Limited standardization refers to the absence of universally accepted protocols and guidelines for sample preparation, staining techniques, and interpretation of results. This lack of standardization poses challenges for researchers and clinicians in achieving consistent and reproducible results across different laboratories and platforms. It leads to variations in staining intensity, specificity, and sensitivity, impacting the reliability and comparability of IHC data. Consequently, this constraint hinders the widespread adoption of IHC in clinical diagnostics and research applications, limiting its potential for guiding treatment decisions and advancing scientific understanding.

Opportunity:

Cancer research and diagnostics

IHC allows for the precise detection and localization of specific proteins within tissue samples, aiding in cancer diagnosis, prognosis, and treatment planning. With advancements in IHC technologies, researchers and clinicians can identify biomarkers associated with different cancer types, enabling personalized medicine approaches. This technique also facilitates the study of tumor microenvironments, contributing to a deeper understanding of cancer biology and potential therapeutic targets. As the demand for accurate cancer diagnosis and targeted therapies continues to grow, the IHC market stands poised to expand further, offering innovative solutions for improved patient care and outcomes.

Threat:

Price sensitivity

The price sensitivity threats are the risks posed by customers being highly responsive to changes in pricing. As IHC involves costly reagents, equipment, and expertise, pricing plays a critical role in purchasing decisions. In a price-sensitive market, customers may opt for cheaper alternatives or reduce their usage if prices rise. This can lead to decreased demand for IHC products and services, impacting revenues and profitability for companies operating in this sector. To mitigate this threat, companies must carefully balance pricing strategies with maintaining product quality and value propositions while also considering the competitive landscape and customer needs.

Covid-19 Impact:

With increased focus on understanding the virus and developing effective diagnostics and therapies, there has been a surge in demand for IHC tests for detecting viral antigens and assessing tissue damage caused by the virus. Additionally, disruptions in healthcare services and research activities during lockdowns have temporarily slowed down market growth. However, the pandemic has also accelerated technological advancements in IHC assays and automation, leading to greater efficiency and accuracy in testing processes. Overall, while the pandemic has posed challenges, it has also highlighted the importance of IHC in disease diagnosis and management, potentially driving long-term growth in the market.

The equipment segment is expected to be the largest during the forecast period

The equipment segment has been experiencing significant growth due to developments in technologies, which have led to the development of more efficient and user-friendly equipment. The increasing prevalence of cancer and chronic diseases has fueled demand for diagnostic techniques like IHC, thereby driving the market for related equipment. Moreover, rising healthcare expenditures globally have enabled healthcare facilities to invest in modern equipment for better patient care. Furthermore, the expanding application of immunohistochemistry techniques in research and drug development has further boosted demand for equipment in this segment.

The research application segment is expected to have the highest CAGR during the forecast period

The research application segment has experienced notable growth due to manufacturing of more sophisticated and sensitive IHC assays, catering to the complex requirements of research studies. The expanding scope of research in areas such as oncology, neuroscience, and immunology has fueled the demand for IHC techniques to analyze tissue samples for biomarker identification and characterization. Moreover, collaborations between academic institutions, research organizations, and biotechnology companies have facilitated the adoption of IHC in diverse research projects. Additionally, the rise in funding for biomedical research globally has further propelled the growth of this segment, enabling the exploration of novel applications and the validation of potential therapeutic targets using IHC.

Region with largest share:

North American region has witnessed substantial growth in the immunohistochemistry (IHC) because of the increasing prevalence of chronic diseases such as cancer, rising demand for personalized medicine, and advancements in diagnostic technologies. Favorable reimbursement policies, robust healthcare infrastructure, and a strong presence of key market players contribute to the expansion of the IHC market in North America. Furthermore, growing investments in research and development activities further propel market growth, with continuous efforts aimed at enhancing the efficiency and accuracy of diagnostic techniques.

Region with highest CAGR:

The Asia-Pacific region has experienced significant growth in the due to a growing number of geriatric population. The rising healthcare expenditure and infrastructure development in countries like China and India have contributed to market expansion. Additionally, advancements in technology, such as automation and digital pathology, have improved efficiency and accuracy in immunohistochemistry procedures, further driving market growth.

Key players in the market

Some of the key players in Immunohistochemistry (IHC) market include Abcam PLC, Agilent Technologies, Inc., Becton Dickinson and Company, Bio SB, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Cell Signaling Technology, Inc., Danaher Corporation, F. Hoffmann-LA Roche AG, Merck KGaA, PerkinElmer, Inc., Takara Bio and Thermo Fisher Scientific Inc.

Key Developments:

In March 2024, Thermo Fisher Scientific Inc. announced the launch of a new CorEvitas syndicated clinical registry in generalized pustular psoriasis (GPP). This registry, which is open to enrollment, is CorEvitas' 10th syndicated disease registry and addresses an unmet need for real-world evidence (RWE) related to the clinical and patient-reported outcomes of patients with GPP.

In February 2024, Danaher Corporation has launched a strategic collaboration with Cincinnati Children's Hospital Medical Center, with the goal of improving patient safety by addressing a leading cause of failure in clinical trials. As part of the Danaher Beacons program, the multi-year collaboration aims to improve liver organoid technology as a drug toxicity screening solution for safeguarding patients.

Products Covered:

  • Antibodies
  • Reagents
  • Kits
  • Equipment
  • Other Products

Applications Covered:

  • Diagnostic Application
  • Research application
  • Other Applications

End Users Covered:

  • Forensic Laboratories
  • Biopharma Companies
  • Hospitals & Diagnostic Laboratories
  • Academic & research Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Immunohistochemistry (IHC) Market, By Product

  • 5.1 Introduction
  • 5.2 Antibodies
    • 5.2.1 Primary antibodies
    • 5.2.2 Secondary antibodies
  • 5.3 Reagents
    • 5.3.1 Diluents
    • 5.3.2 Proteolytic Enzymes
    • 5.3.3 Blocking Sera and Reagents
    • 5.3.4 Fixation Reagents
    • 5.3.5 Histological Stains
    • 5.3.6 Chromogenic Substrates
    • 5.3.7 Organic Solvents
    • 5.3.8 Stabilizers
    • 5.3.9 Mounting Solutions
    • 5.3.10 Antigen Retrieval Solutions
    • 5.3.11 Other Reagents
  • 5.4 Kits
    • 5.4.1 IHC Kits for Animal tissue
    • 5.4.2 IHC Kits for Human tissue
  • 5.5 Equipment
    • 5.5.1 Slide Scanners
    • 5.5.2 Automated Cover Slippers
    • 5.5.3 Microtomes
    • 5.5.4 Visualization Equipment
    • 5.5.5 Slide Labelers
    • 5.5.6 Tissue Microarrays
    • 5.5.7 Paraffin Dispensers
    • 5.5.8 Slide-staining Systems
    • 5.5.9 Tissue Processing Systems
    • 5.5.10 Other Equipment
  • 5.6 Other Products

6 Global Immunohistochemistry (IHC) Market, By Application

  • 6.1 Introduction
  • 6.2 Diagnostic Application
    • 6.2.1 Cancer
    • 6.2.2 Infectious diseases
    • 6.2.3 Autoimmune diseases
    • 6.2.4 Nephrological diseases
    • 6.2.5 Neurological diseases
    • 6.2.6 Ophthalmic
    • 6.2.7 Dental Diseases
    • 6.2.8 Cardiovascular
    • 6.2.9 Dermatological
    • 6.2.10 Other Diagnostic Applications
  • 6.3 Research application
    • 6.3.1 Drug development and Testing
    • 6.3.2 Developmental Biology
    • 6.3.3 Stem Cell Research
    • 6.3.4 Forensic applications
    • 6.3.5 Other Research Applications
  • 6.4 Other Applications

7 Global Immunohistochemistry (IHC) Market, By End User

  • 7.1 Introduction
  • 7.2 Forensic Laboratories
  • 7.3 Biopharma Companies
  • 7.4 Hospitals & Diagnostic Laboratories
  • 7.5 Academic & research Institutes
  • 7.6 Other End Users

8 Global Immunohistochemistry (IHC) Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Abcam PLC
  • 10.2 Agilent Technologies, Inc.
  • 10.3 Becton Dickinson and Company
  • 10.4 Bio SB
  • 10.5 Bio-Rad Laboratories, Inc.
  • 10.6 Bio-Techne Corporation
  • 10.7 Cell Signaling Technology, Inc.
  • 10.8 Danaher Corporation
  • 10.9 F. Hoffmann-LA Roche AG
  • 10.10 Merck KGaA
  • 10.11 PerkinElmer, Inc.
  • 10.12 Takara Bio
  • 10.13 Thermo Fisher Scientific Inc.

List of Tables

  • Table 1 Global Immunohistochemistry (IHC) Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Immunohistochemistry (IHC) Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Immunohistochemistry (IHC) Market Outlook, By Antibodies (2021-2030) ($MN)
  • Table 4 Global Immunohistochemistry (IHC) Market Outlook, By Primary antibodies (2021-2030) ($MN)
  • Table 5 Global Immunohistochemistry (IHC) Market Outlook, By Secondary antibodies (2021-2030) ($MN)
  • Table 6 Global Immunohistochemistry (IHC) Market Outlook, By Reagents (2021-2030) ($MN)
  • Table 7 Global Immunohistochemistry (IHC) Market Outlook, By Diluents (2021-2030) ($MN)
  • Table 8 Global Immunohistochemistry (IHC) Market Outlook, By Proteolytic Enzymes (2021-2030) ($MN)
  • Table 9 Global Immunohistochemistry (IHC) Market Outlook, By Blocking Sera and Reagents (2021-2030) ($MN)
  • Table 10 Global Immunohistochemistry (IHC) Market Outlook, By Fixation Reagents (2021-2030) ($MN)
  • Table 11 Global Immunohistochemistry (IHC) Market Outlook, By Histological Stains (2021-2030) ($MN)
  • Table 12 Global Immunohistochemistry (IHC) Market Outlook, By Chromogenic Substrates (2021-2030) ($MN)
  • Table 13 Global Immunohistochemistry (IHC) Market Outlook, By Organic Solvents (2021-2030) ($MN)
  • Table 14 Global Immunohistochemistry (IHC) Market Outlook, By Stabilizers (2021-2030) ($MN)
  • Table 15 Global Immunohistochemistry (IHC) Market Outlook, By Mounting Solutions (2021-2030) ($MN)
  • Table 16 Global Immunohistochemistry (IHC) Market Outlook, By Antigen Retrieval Solutions (2021-2030) ($MN)
  • Table 17 Global Immunohistochemistry (IHC) Market Outlook, By Other Reagents (2021-2030) ($MN)
  • Table 18 Global Immunohistochemistry (IHC) Market Outlook, By Kits (2021-2030) ($MN)
  • Table 19 Global Immunohistochemistry (IHC) Market Outlook, By IHC Kits for Animal tissue (2021-2030) ($MN)
  • Table 20 Global Immunohistochemistry (IHC) Market Outlook, By IHC Kits for Human tissue (2021-2030) ($MN)
  • Table 21 Global Immunohistochemistry (IHC) Market Outlook, By Equipment (2021-2030) ($MN)
  • Table 22 Global Immunohistochemistry (IHC) Market Outlook, By Slide Scanners (2021-2030) ($MN)
  • Table 23 Global Immunohistochemistry (IHC) Market Outlook, By Automated Cover Slippers (2021-2030) ($MN)
  • Table 24 Global Immunohistochemistry (IHC) Market Outlook, By Microtomes (2021-2030) ($MN)
  • Table 25 Global Immunohistochemistry (IHC) Market Outlook, By Visualization Equipment (2021-2030) ($MN)
  • Table 26 Global Immunohistochemistry (IHC) Market Outlook, By Slide Labelers (2021-2030) ($MN)
  • Table 27 Global Immunohistochemistry (IHC) Market Outlook, By Tissue Microarrays (2021-2030) ($MN)
  • Table 28 Global Immunohistochemistry (IHC) Market Outlook, By Paraffin Dispensers (2021-2030) ($MN)
  • Table 29 Global Immunohistochemistry (IHC) Market Outlook, By Slide-staining Systems (2021-2030) ($MN)
  • Table 30 Global Immunohistochemistry (IHC) Market Outlook, By Tissue Processing Systems (2021-2030) ($MN)
  • Table 31 Global Immunohistochemistry (IHC) Market Outlook, By Other Equipment (2021-2030) ($MN)
  • Table 32 Global Immunohistochemistry (IHC) Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 33 Global Immunohistochemistry (IHC) Market Outlook, By Application (2021-2030) ($MN)
  • Table 34 Global Immunohistochemistry (IHC) Market Outlook, By Diagnostic Application (2021-2030) ($MN)
  • Table 35 Global Immunohistochemistry (IHC) Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 36 Global Immunohistochemistry (IHC) Market Outlook, By Infectious diseases (2021-2030) ($MN)
  • Table 37 Global Immunohistochemistry (IHC) Market Outlook, By Autoimmune diseases (2021-2030) ($MN)
  • Table 38 Global Immunohistochemistry (IHC) Market Outlook, By Nephrological diseases (2021-2030) ($MN)
  • Table 39 Global Immunohistochemistry (IHC) Market Outlook, By Neurological diseases (2021-2030) ($MN)
  • Table 40 Global Immunohistochemistry (IHC) Market Outlook, By Ophthalmic (2021-2030) ($MN)
  • Table 41 Global Immunohistochemistry (IHC) Market Outlook, By Dental Diseases (2021-2030) ($MN)
  • Table 42 Global Immunohistochemistry (IHC) Market Outlook, By Cardiovascular (2021-2030) ($MN)
  • Table 43 Global Immunohistochemistry (IHC) Market Outlook, By Dermatological (2021-2030) ($MN)
  • Table 44 Global Immunohistochemistry (IHC) Market Outlook, By Other Diagnostic Applications (2021-2030) ($MN)
  • Table 45 Global Immunohistochemistry (IHC) Market Outlook, By Research application (2021-2030) ($MN)
  • Table 46 Global Immunohistochemistry (IHC) Market Outlook, By Drug development and Testing (2021-2030) ($MN)
  • Table 47 Global Immunohistochemistry (IHC) Market Outlook, By Developmental Biology (2021-2030) ($MN)
  • Table 48 Global Immunohistochemistry (IHC) Market Outlook, By Stem Cell Research (2021-2030) ($MN)
  • Table 49 Global Immunohistochemistry (IHC) Market Outlook, By Forensic applications (2021-2030) ($MN)
  • Table 50 Global Immunohistochemistry (IHC) Market Outlook, By Other Research Applications (2021-2030) ($MN)
  • Table 51 Global Immunohistochemistry (IHC) Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 52 Global Immunohistochemistry (IHC) Market Outlook, By End user (2021-2030) ($MN)
  • Table 53 Global Immunohistochemistry (IHC) Market Outlook, By Forensic Laboratories (2021-2030) ($MN)
  • Table 54 Global Immunohistochemistry (IHC) Market Outlook, By Biopharma Companies (2021-2030) ($MN)
  • Table 55 Global Immunohistochemistry (IHC) Market Outlook, By Hospitals & Diagnostic Laboratories (2021-2030) ($MN)
  • Table 56 Global Immunohistochemistry (IHC) Market Outlook, By Academic & research Institutes (2021-2030) ($MN)
  • Table 57 Global Immunohistochemistry (IHC) Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.